Cardiovascular translational medicine (III). Genomics and proteomics in heart failure research

Arantxa González1, Begoña López, Javier Beaumont

  • 1Area de Ciencias Cardiovasculares, Centro de Investigación Médica, Universidad de Navarra, 31008 Pamplona, Navarra, Spain.

Insights

Omics sciences, including genomics and proteomics, offer new approaches to understand heart failure. These methods aid in identifying novel biomarkers and therapeutic targets for improved patient outcomes.

Area of Science:

  • Cardiovascular Research
  • Genomics
  • Proteomics
  • Metabonomics

Background:

  • Heart failure is a leading cause of morbidity and mortality globally.
  • Current prevention and treatment strategies for heart failure have limitations.
  • Novel approaches are needed to advance heart failure research.

Purpose of the Study:

  • To review the role of omics sciences in heart failure research.
  • To evaluate the contribution of genomics and proteomics to understanding heart failure.
  • To highlight the potential of omics for new biomarkers and therapies.

Main Methods:

  • Review of fundamental principles of omics sciences.
  • Analysis of gene expression microarrays (genomics).
  • Evaluation of 2D electrophoresis with mass spectrometry (proteomics).

Main Results:

  • Omics methodologies have transformed biological approaches to disease.
  • Genomics and proteomics provide insights into heart failure mechanisms.
  • Omics can facilitate the development of diagnostic profiles and therapeutic templates.

Conclusions:

  • Omics sciences are crucial for advancing heart failure research.
  • Application of omics can lead to improved understanding and management of heart failure.
  • Future research should leverage omics for novel diagnostic and therapeutic strategies.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...